198 related articles for article (PubMed ID: 19404046)
1. [Atorvastatin in primary prevention].
Kültürsay H
Turk Kardiyol Dern Ars; 2009 Mar; 37 Suppl 2():17-22. PubMed ID: 19404046
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of atorvastatin in the prevention of cardiovascular events in diabetic patients: a French adaptation of CARDS.
Lafuma A; Colin X; Solesse A
Arch Cardiovasc Dis; 2008 May; 101(5):327-32. PubMed ID: 18656091
[TBL] [Abstract][Full Text] [Related]
3. Atorvastatin: a pharmacoeconomic review of its use in the primary and secondary prevention of cardiovascular events.
Plosker GL; Lyseng-Williamson KA
Pharmacoeconomics; 2007; 25(12):1031-53. PubMed ID: 18047388
[TBL] [Abstract][Full Text] [Related]
4. [Analysis of cost-effectiveness of simvastatin versus atorvastatin in the secondary prevention of cardiovascular events within the Brazilian public healthcare system].
Araujo DV; Ribeiro de Souza CP; Bahia LR; Rey HC; Dos Santos Junior B; Tura BR; Berwanger O; Buehler AM; Silva MT
Value Health; 2011; 14(5 Suppl 1):S29-32. PubMed ID: 21839894
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of intensive atorvastatin treatment in high-risk patients compared with usual care in a postgeneric statin market: economic analysis of the Aggressive Lipid-lowering Initiation Abates New Cardiac Events (ALLIANCE) study.
Mullins CD; Rattinger GB; Kuznik A; Koren MJ
Clin Ther; 2008; 30 Pt 2():2204-16. PubMed ID: 19281915
[TBL] [Abstract][Full Text] [Related]
6. The cost of stroke prevention.
Samuelson RM; Levy EI; Siddiqui AH; Hopkins LN
Stroke; 2009 Feb; 40(2):e41-2; author reply e43. PubMed ID: 19095968
[No Abstract] [Full Text] [Related]
7. The pharmaco-economics of peri-operative statin therapy.
Biccard BM; Sear JW; Foëx P
Anaesthesia; 2005 Nov; 60(11):1059-63. PubMed ID: 16229688
[TBL] [Abstract][Full Text] [Related]
8. An economic evaluation of atorvastatin for primary prevention of cardiovascular events in type 2 diabetes.
Ramsey SD; Clarke LD; Roberts CS; Sullivan SD; Johnson SJ; Liu LZ
Pharmacoeconomics; 2008; 26(4):329-39. PubMed ID: 18370567
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of intensive lipid lowering therapy with 80 mg of atorvastatin, versus 10 mg of atorvastatin, for secondary prevention of cardiovascular disease in Canada.
Wagner M; Goetghebeur M; Merikle E; Pandya A; Chu P; Taylor DC
Can J Clin Pharmacol; 2009; 16(2):e331-45. PubMed ID: 19531812
[TBL] [Abstract][Full Text] [Related]
10. Cost effectiveness of atorvastatin in patients with type 2 diabetes mellitus: a pharmacoeconomic analysis of the collaborative atorvastatin diabetes study in the belgian population.
Annemans L; Marbaix S; Webb K; Van Gaal L; Scheen A
Clin Drug Investig; 2010; 30(2):133-42. PubMed ID: 20067331
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of rosuvastatin vs generic atorvastatin in Spain.
Barrios V; Lobos JM; Serrano A; Brosa M; Capel M; Alvarez Sanz C
J Med Econ; 2012; 15 Suppl 1():45-54. PubMed ID: 22954062
[TBL] [Abstract][Full Text] [Related]
12. Cost effectiveness of HMG-CoA reductase inhibition in Canada.
Russell MW; Huse DM; Miller JD; Kraemer DF; Hartz SC
Can J Clin Pharmacol; 2001; 8(1):9-16. PubMed ID: 11283756
[TBL] [Abstract][Full Text] [Related]
13. The value of atorvastatin over the product life cycle in the United States.
Grabner M; Johnson W; Abdulhalim AM; Kuznik A; Mullins CD
Clin Ther; 2011 Oct; 33(10):1433-43. PubMed ID: 21955936
[TBL] [Abstract][Full Text] [Related]
14. [Atorvastatin (Lipitor)].
Carpentier Y; Ducobu J; Sternon J
Rev Med Brux; 1999 Oct; 20(5):427-33. PubMed ID: 10582478
[TBL] [Abstract][Full Text] [Related]
15. Results of a Markov model analysis to assess the cost-effectiveness of a single tablet of fixed-dose amlodipine and atorvastatin for the primary prevention of cardiovascular disease in Korea.
Liew D; Park HJ; Ko SK
Clin Ther; 2009 Oct; 31(10):2189-203; discussion 2150-1. PubMed ID: 19922890
[TBL] [Abstract][Full Text] [Related]
16. Pharmacoeconomic evaluation of the effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes.
Schwartz GG; Ganz P; Waters D; Arikian S
Am J Cardiol; 2003 Nov; 92(9):1109-12. PubMed ID: 14583367
[TBL] [Abstract][Full Text] [Related]
17. The lifetime cost effectiveness of amlodipine-based therapy plus atorvastatin compared with atenolol plus atorvastatin, amlodipine-based therapy alone and atenolol-based therapy alone: results from ASCOT1.
Lindgren P; Buxton M; Kahan T; Poulter NR; Dahlöf B; Sever PS; Wedel H; Jönsson B;
Pharmacoeconomics; 2009; 27(3):221-30. PubMed ID: 19354342
[TBL] [Abstract][Full Text] [Related]
18. A model to assess the cost effectiveness of statins in achieving the UK National Service Framework target cholesterol levels.
Wilson K; Marriott J; Fuller S; Lacey L; Gillen D
Pharmacoeconomics; 2003; 21 Suppl 1():1-11. PubMed ID: 12648030
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.
Plans-Rubió P
Am J Cardiovasc Drugs; 2006; 6(3):177-88. PubMed ID: 16780391
[TBL] [Abstract][Full Text] [Related]
20. [Atorvastatin in correction of metabolic syndrome: clinico-economical assessment of efficacy].
Khokhlov AL; Zhilina AN; Buĭdina TA
Kardiologiia; 2006; 46(11):57-62. PubMed ID: 17183751
[No Abstract] [Full Text] [Related]
[Next] [New Search]
